A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

• Drug: 3 mg PF-06412562
  
  oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
• Drug: 10 mg PF-06412562
  
  oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
• Drug: 25 mg PF-06412562
  
  oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
• Drug: PF-06412562 TBD mg
  
  oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts

• Experimental: Cohort 1
  
  Intervention: Drug: 3 mg PF-06412562
• Experimental: Cohort 2
  
  Intervention: Drug: 10 mg PF-06412562
• Experimental: Cohort 3
  
  Intervention: Drug: 25 mg PF-06412562
• Experimental: Optional Cohort 4
  
  Intervention: Drug: PF-06412562 TBD mg
• Experimental: Optional Cohort 5
  
  Intervention: Drug: PF-06412562 TBD mg

Inclusion Criteria:

• Healthy female subjects of non-childbearing potential and/or male subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs);

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.